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ackground & Aims: TLR4 is a cell-surface signaling
eceptor involved in the recognition and host response
o Helicobacter pylori. The TLR4896A>G polymor-
hism linked with impaired reactivity to bacterial lipo-
olysaccharide may play a role in gastric carcinogenesis.
ethods: We assessed associations with premalignant
astric changes in 149 relatives of gastric cancer pa-
ients, including 45 with hypochlorhydria and gastric
trophy. We also genotyped 2 independent Caucasian
opulation-based case–control studies of upper gastro-
ntestinal tract cancer, initially in 312 noncardia gastric
arcinoma cases and 419 controls and then in 184 non-
ardia gastric carcinomas, 123 cardia carcinomas, 159
sophageal cancers, and 211 frequency-matched con-
rols. Odds ratios were computed from logistic models
nd adjusted for potential confounding factors.
esults: TLR4896G carriers had an 11-fold (95% con-
dence interval [CI], 2.5–48) increased odds ratio (OR)
or hypochlorhydria; the polymorphism was unassoci-
ted with gastric acid output in the absence of H pylori
nfection. Carriers also had significantly more severe
astric atrophy and inflammation. Seventeen percent of
astric carcinoma patients in the initial study and 15%
f the noncardia gastric carcinoma patients in the rep-
ication study had 1 or 2 TLR4 variant alleles vs 8% of
oth control populations (combined OR  2.3; 95% CI
1.6–3.4). In contrast, prevalence of TLR4896G was
ot significantly increased in esophageal squamous cell
2%, OR  0.2) or adenocarcinoma (9%, OR  1.4) or
astric cardia carcinoma (11%, OR  1.4).
onclusions: Our data suggest that the TLR4896A>G
olymorphism is a risk factor for noncardia gastric
arcinoma and its precursors. The findings underscore
he role of the host innate immune response in outcome
f H pylori infection.
astric cancer remains a major health problem de-
spite the recent decline in the incidence of this
alignancy in the developed world. The global burden is
et to increase with around 1.1 million new cases ex-ected in the year 2010.1 Helicobacter pylori infection is
he most recognized etiologic risk factor for this ma-
ignancy.2 The infection causes a chronic gastritis that is
he precursor to all the pathophysiologic abnormalities
haracteristic of gastric carcinogenesis.3 The most impor-
ant of these abnormalities are gastric atrophy and hy-
ochlorhydria, which develop as a direct result of the
hronic inflammation induced by the infection.4 How-
ver, these precancerous abnormalities only develop in a
roportion of infected subjects that vary among different
thnic groups. The reason for the variable phenotypic
xpression of the infection is multifactorial, and com-
ines the effects of the host genetic constitution, bacte-
ial virulence factors, and environmental exposures.
We and others have recently reported that proinflam-
atory cytokine gene polymorphisms in the interleu-
in-1B (encoding IL-1), IL-1RN (encoding the naturally
ccurring receptor antagonist for IL-1), IL-10, and tu-
or necrosis factor alpha (TNF), all contribute to in-
reased risk of gastric carcinoma and its precursors (gas-
ric atrophy and hypochlorhydria).5–9 These genetic risk
arkers belong to inflammation-related cytokines that
xert their effect as part of the innate and adaptive
mmune response against the infection. Equally important
n the appropriate handling of H pylori infection are the
eceptors of the innate immune response. It is conceivable
hat functionally relevant polymorphisms in genes of such
eceptors could affect the magnitude and subsequent direc-
ion of the host’s response against the infection.
Because the majority of H pylori cells do not invade the
astric mucosa, this inflammatory response is triggered
hrough contact of H pylori with the gastric epithelia and
ubsequent injection of bacterial products into host
Abbreviations used in this paper: CI, confidence interval; GCR, gas-
ric cancer patients; IL, interleukin beta; LPS, lipopolysaccharide; OR,
dds ratio; PAOpg, pentagastrin stimulation; PCR, polymerase chain
eaction; TNF, tumor necrosis factor alpha; TRL4, Toll-like receptor 4.





















































































































906 HOLD ET AL GASTROENTEROLOGY Vol. 132, No. 3ells.10 Toll-like receptor 4 (TLR4), the lipopolysaccharide
LPS) receptor, was initially identified as a potential bind-
ng receptor for H pylori on gastric epithelial cells, al-
hough more recent data are controversial. It is more
ikely that interaction with macrophage/monocyte TLR4
s more relevant for H pylori infection. TLR4 belongs to a
amily of pattern recognition receptors, of which there
re currently 11 members, that activate pro-inflammatory
ignaling pathways in response to microbes or pathogen-
ssociated molecular patterns.11 TLR4, in conjunction
ith CD14 and MD-2, transduces signals through
yD88, Toll/IL-1 receptor domain, and TRAF6. This
romotes transcription of genes, which are involved in
mmune activation including the transcription factor nu-
lear factor -B (NF-B) and also mitogen-activated pro-
ein (MAP) kinase pathways.12
Recently, a functional polymorphism at position 896
n exon 4 of the TLR4 gene has been described (dbSNP
D: rs4986790).13 This AG transition results in replace-
ent of a conserved aspartic acid residue with glycine at
mino acid 299 (Asp299Gly), and alteration in the extra-
ellular domain of the TLR4 receptor. This renders car-
iers hyporesponsive to LPS challenge by either disrupt-
ng transport of TLR4 to the cell membrane or by
mpairing ligand binding or protein interactions.13 The
utation has been associated with a variety of inflam-
atory, infectious and neoplastic conditions including
therosclerosis, myocardial infarction, inflammatory
owel disease, septic shock, and prostate cancer.14 –19 Re-
ent work demonstrates that defective signaling through
he TLR4 receptor ultimately leads to an exaggerated
nflammatory response with severe tissue destruction,
ven though the initial immune response may be
lunted. This is due to inadequate production of IL-10-
ecreting type 1 regulatory cells.20
Thus, we hypothesized that the TLR4896AG poly-
orphism would be associated with an exaggerated and
estructive chronic inflammatory phenotype in H pylori-
nfected subjects. This phenotype would be characterized
y gastric atrophy and hypochlorhydria, the hallmarks of
ubsequent increased risk of gastric carcinoma. We fur-
her hypothesized that the same polymorphism might
ncrease the risk of gastric carcinoma itself. The aim of
ur study was therefore to test the effect of this polymor-
hism on the H pylori-induced gastric phenotype and the




To determine whether the TLR4896AG poly-
orphism is associated with differing outcomes of
pylori infection, we studied a cohort of 149 healthy
aucasian first-degree relatives of gastric cancer patients
GCR) from the West of Scotland. These subjects had (een extensively investigated in relation to their H pylori
tatus (assessed by 14C-urea breath test, serology, rapid
lide urease test, culture, and histology). Their gastric
henotype was defined histologically by assessment of
ntral and corpus biopsies for H pylori density, combined
nflammatory scores (active and chronic giving a maxi-
um score of 6, range 0 – 6), and presence of mucosal
trophy (score 0 –3).21 In addition, these subjects had
heir peak acid output measured in response to penta-
astrin stimulation (PAOpg) and the subjects were desig-
ated as having hypochlorhydria if their PAOpg was 15
mol/h.22 Corpus atrophy was absent in all subjects with
PAOpg 15 mmol/h. The 149 subjects were then clas-
ified into 3 distinct groups: (1) 45 subjects had H pylori
nfection, hypochlorhydria, and gastric atrophy; (2) 58
ubjects had H pylori infection but no hypochlorhydria or
orpus atrophy; (3) 46 subjects had no evidence of H
ylori infection and had normal acid secretion and gastric
orphology. One hundred unselected cord blood DNA
amples from the West of Scotland were used as popu-
ation controls for the genetic studies. Data were avail-
ble to allow assessment of the effect of the TLR4 geno-
ype on histologic and physiologic parameters in
ddition to estimating the risk of each outcome.
To assess the effect of the polymorphisms on the risks
f upper gastrointestinal tract cancers, 2 independent
ase– control studies were utilized. The first was a gastric
ancer case– control study derived from a Caucasian pop-
lation in Warsaw, Poland, in which there were DNA
amples available from 312 noncardia gastric adenocar-
inoma patients and 419 controls.23 The second was a
ulticenter esophageal and gastric cancer study con-
ucted in 3 geographic areas of the United States with
opulation-based tumor registries24; DNA samples were
vailable from 307 subjects with gastric adenocarcinoma
123 cardia and 184 noncardia, 90% Caucasian), 159
ubjects with esophageal cancer (52 with squamous cell
arcinoma and 107 with adenocarcinoma, 90% Cauca-
ian), and 211 population controls (94% Caucasian).
Genotyping
The TLR4896AG polymorphism was initially
ssessed in the GCR subjects using the restriction frag-
ent length polymorphism assay described by Lorenz.25
riefly, the locus was amplified by polymerase chain re-
ction (PCR), with 1 PCR primer altered to create an NcoI
estriction site for the variant G amplicon (Table 1).
eactions were performed in a volume of 25 L contain-
ng 50 ng of DNA, 10 mmol/L Tris–HCl pH 9.0, 50
mol/L KCl; 1.5 mmol/L MgCl2, 200 mol/L each of
eoxyadenosine triphosphate, deoxycytidine triphos-
hate (dTTP), and deoxyguanosine triphosphate, 10
mol of each primer (MWG Biotech, Germany), and 1
nit of Taq polymerase (Bioline, London, England). Re-
ctions were run on a Techne Genius thermocycler































































































March 2007 TLR4 MUTATION AND GASTRIC CANCER 907itions: 95oC for 4 minutes, then 30 cycles of 95oC for 30
econds, 55oC for 30 seconds, and 72oC for 30 seconds,
ollowed by a final extension of 72oC for 10 minutes. Five
icroliters of the resultant PCR products were used for
n overnight digest with the restriction enzyme NcoI
New England Biolabs, Herts, England). Digestion prod-
cts were separated by electrophoresis on 2.5% agarose
els.
All the GCR genotypes were subsequently confirmed
ith a 5= nuclease PCR assay (Taqman), using minor
roove binding probes 5=-labeled with FAM (6-carboxy-
uoresceine) or VIC fluorochromes to detect the G or A
llele, respectively (Table 1). PCR amplification was per-
ormed in a volume of 25 L containing 50 ng genomic
NA, 1 TaqMan Universal Master Mix (PE Applied
iosystems, Foster City, CA), 200 nmol/L for each probe,
nd 900 nmol/L for primers. Thermal cycling of optical
lates was performed on a GeneAmp PCR System 9700
PE Applied Biosystems) using the following conditions:
0oC for 2 minutes, 95oC for 10 minutes, then 40 cycles
f 95oC for 15 seconds and 60oC for 1 minute. Endpoint
nalysis was performed in an ABI PRISM 7700 Sequence
etection System (PE Applied Biosystems). Genotyping
or the gastric cancer case– control studies was done us-
ng the restriction fragment length polymorphism and
aqman assays for all samples with 100% concordance.
oth assays were validated by direct sequencing of se-
ected samples of each genotype.
Statistical Analysis
The effect of the TLR4896 AG polymorphism
n acid secretory status and histologic parameters (in-
ammation and atrophy) in the GCR study was assessed
sing the Mann-Whitney U test with significance taken at
he 5% level.
Hardy-Weinberg equilibrium of alleles at individual
oci was assessed by 2 statistics. Odds ratios (OR) with
ornfield 95% confidence intervals (CIs) were computed
y logistic regression using STATA version 7.0 software
STATA Press, College Station, TX). ORs for hypochlo-
hydria in the GCR study were age adjusted (categorized
s 35, 36 – 45, 46 –55, and 55 years) because of its age
ependence,22 and their CIs were based on robust vari-
nce estimates,26 adjusted for within-family correlation,
o account for sampling of several members of a given




TaqMan F: 5=- TGACCATTGAAGAATTCCGA
R: 5=- CACCAGGGAAAATGAAGAA
, forward primer; R, reverse primer; RFLP, restriction fragment lengt
Underlined base in primer indicates the nucleotide altered to createamily. ORs for the different cancers were adjusted for oge (categorized as younger than 50, 50 –59, 60 – 69, and
0 years or older), sex, and race (categorized as White and
ll other). Additional models were adjusted for the effects
f the genetic polymorphisms on one another, histologic
ubtype (Lauren classification), cigarette smoking (cate-
orized as current, former, and never), alcohol consump-
ion (categorized as greater or less than 1 drink per
onth), history of gastroesophageal reflux disease, body
ass index (in quartiles), history of gastric or duodenal
lcer disease, H pylori serologic status, and family history
f esophageal or gastric cancer.
The institutional review boards of the participating
enters approved the study, and written informed con-
ent was obtained from all subjects.
Results
In all 3 control populations, the alleles at the
LR4896 locus were in Hardy-Weinberg equilibrium,
ith nonsignificant 2 values. The frequency of the vari-
nt allele in the 3 control populations ranged from 3.9%
o 4.3%, and was similar to those reported from other
tudies of Caucasians. The homozygous TLR4896 G/G
enotype was rare, and the A/G and G/G carrier geno-
ypes were combined in the genetic association analyses.
Association of TLR4896A>G
Polymorphism With Risks of H pylori
Infection and Premalignant Gastric
Abnormalities
The TLR4 polymorphism was not associated with
isk of H pylori infection in the GCR study. Comparing all
nfected subjects (with and without precancerous abnor-
alities) to noninfected subjects, the adjusted OR for
nfection was 1.2 (95% CI, 0.4 – 4.0).
There was a significantly higher frequency of the vari-
nt G allele in H pylori–infected subjects with hypochlo-
hydria and gastric atrophy, compared to infected GCR
ith neither abnormality. Thirteen (29%) of the 45 GCR
ith hypochlorhydria and atrophy were variant carriers
ompared with only 2 (3%) of 58 infected subjects with-
ut these precancerous changes. The odds ratio of hypo-
hlorhydria/atrophy for carriers of the G allele was 11.0
95% CI, 2.5– 48), adjusted for age and multiple sampling
rom the same family (Table 2).
































































908 HOLD ET AL GASTROENTEROLOGY Vol. 132, No. 3ompared with the 88 noncarriers (median of 1.1
mol/h vs. 23.2 mmol/h, P  .001) (Figure 1). Within
he subgroup of 45 GCR with hypochlorhydria and at-
ophy, the TLR4896 G carriers had more severe histo-
ogic changes than did the noncarriers. The median com-
ined corpus inflammatory score was 6 (range: 4 – 6) for
he 13 carriers vs. 4 (range: 3– 6) for the 32 noncarriers,
nd the median atrophy score was 2 (range: 1–3) for the
arriers vs. 1 (range: 1–3) for the noncarriers (P  .03 and
 .02, respectively; Figures 2A and B).
Association of TLR4896A>G
Polymorphism With Risk of Gastric
Carcinoma
The TLR4896 G allele was similarly associated
ith the risk of gastric carcinoma. In the Polish study,
7% of the gastric carcinoma patients had 1 or 2 TLR4
ariant alleles vs. 8% of control subjects (Table 3). The
ge, sex-adjusted OR of noncardia gastric cancer for car-
iers of the G allele was 2.5 (95% CI, 1.6 – 4.0).
able 2. Genotype Frequencies and Adjusted Odds Ratios (O
TLR4896AG Polymorphism in Gastric Cancer Re
Genotype
H pylori positive GCR




Odds ratio for low acid vs normal/high acid, adjusted for age and w
OR for H pylori-positive GCR vs H pylori-negative GCR.The association with noncardia gastric cancer was con-
rmed in the multicenter U.S. study. Fifteen percent of
ases had at least 1 copy of the variant TLR4896G allele,
ompared with only 8% of the control population (OR 
.1, 95% CI, 1.1– 4.2; Table 3). However, the polymor-
hism was not significantly associated with risk of the
ther upper gastrointestinal cancers. TLR4896 G was
resent in 11% of subjects with gastric cardia carcinoma
OR  1.4, 95% CI, 0.6 –3.0), 9% of esophageal adenocar-
inoma (OR  1.4, 95% CI, 0.6 –3.2), and 2% of esopha-
eal squamous cell carcinoma (OR  0.2, 95% CI, 0.02–
.7; Table 4).
For increased precision of the effect estimate for non-
ardia gastric carcinoma, we combined the data from the
case– control studies. With a total of 496 cases and 630
ontrols, the combined adjusted OR for noncardia gas-
ric carcinoma was 2.3 (95% CI, 1.6 –3.4; Table 3). The
Rs for noncardia gastric carcinoma did not significantly
iffer between the intestinal (OR  2.2, 95% CI, 1.4 –3.4)
and Cornfield 95% Confidence Intervals [CIs]) for the
s (GCR) and Population Controls
5% CI)a
H pylori negative GCR
(n  46) OR (95% CI)b
Population controls
(n  100)
.0 42 1.0 92
.5–48) 4 0.9 (0.2–3.8) 8
0 0
amily sampling.
Figure 1. Peak acid output to
pentagastrin (PAOpg) stimulation
for H pylori-positive and -neg-


































































March 2007 TLR4 MUTATION AND GASTRIC CANCER 909nd diffuse (OR  3.0, 95% CI, 1.8 –5.1) types of gastric
arcinoma.
Combined Effect of TLR4896A>G and
Proinflammatory IL-1 Polymorphisms on
Risk of Noncardia Gastric Carcinoma
As previously reported, carriage of the pro-inflam-
atory IL-1B-511 T allele and homozygosity for allele 2
f the IL-1RN VNTR are associated with increased risk of
astric carcinoma. The independent effect of TLR4896
G was similar in models that included these markers
f cytokine genes (data not shown). In a model combin-
ng these 2 types of markers, the ORs for gastric carci-
oma in the presence of neither, an IL-1 pro-inflamma-
ory genotype alone, carriage of TLR4896 G alone, or
oth an IL-1 pro-inflammatory genotype and TLR4896
were 1.0, 2.4, 3.0, and 5.0, respectively (Table 5).
Discussion
In the present study, we have shown that a func-
ional TLR4 polymorphism is associated with the devel-
pment of the premalignant gastric abnormalities of
ypochlorhydria and atrophy, and also with increased
igure 2. (A) Box-and-whisker plot of combined inflammatory scores
asis of TRL4896 AG polymorphism. The bold lines represent med
he whiskers of the plot include outliers. (B) Box-and-whisker plot of
tratified on the basis of TLR4896 AG polymorphism. The bold lines r
f the data. The whiskers of the plot include outliers.
able 3. Genotype Frequencies and Age-, Sex-, Race-Adjusted






(n  312) OR (95% CI)
A/A 387 258 1.0
A/G 31 51 2.5 (1.6–4.0)
G/G 1 3isk of noncardia gastric carcinoma. The association with
oncardia gastric carcinoma was confirmed in 2 indepen-
ent population-based case– control studies. No associa-
ion was seen with cancer of the cardia or esophagus.
lthough this polymorphism has been associated with
isk of other inflammatory conditions, to our knowledge
his is the first report of an association with gastric
arcinoma and its precursors and the first to show asso-
iations between gastric carcinoma and a toll-like recep-
or gene, a classic example of the innate immune re-
ponse. The magnitude of the increased risk, a combined
R for the 2 studies of 2.3, is entirely in keeping with a
odest genetic contribution to a complex and multifac-
orial human cancer. The polymorphism had no impact
n the risk of H pylori infection itself, but the findings
nderscore the importance of host genetic factors in
etermining the clinical outcome of the infection. They
lso shed considerable light on the pathogenesis of
pylori-induced gastric carcinoma and the role of the
nnate immune response in it.
The association of the TLR4896AG polymorphism
ith both gastric carcinoma and its precursor lesions
mplies that it is relevant to the entire multistage process
pylori ve subjects with hypochlorhydria and atrophy stratified on the
and the span of the box represents the interquartile range of the data.
hy scores in H pylori ve subjects with hypochlorhydria and atrophy
ent medians, and the span of the box represents the interquartile range
ds Ratios (ORS) (and Cornfield 95% Confidence Intervals
Gastric Carcinoma Cases and Controls, Polish and
ntrols
211) US cases (n  184) OR (95% CI)
Combined OR
(95% CI)
94 156 1.0 1.0










































































































910 HOLD ET AL GASTROENTEROLOGY Vol. 132, No. 3f gastric carcinogenesis, which starts with H pylori col-
nization of the gastric mucosa. Subjects with this poly-
orphism have an increased risk of severe inflammation
nd subsequently, development of hypochlorhydria and
astric atrophy, which are regarded as the most impor-
ant precancerous abnormalities.
We propose that subjects with a pro-inflammatory
enetic makeup based on a combination of cytokine gene
arkers (eg, IL-1, TNF-, IL-10) and the innate immune
eceptors (eg, TLR4), respond to H pylori infection by
reating an environment within the stomach that is
hronically inflamed and with reduced acidity. This en-
ironment is conducive to the growth of other bacteria
ithin the gastric milieu, leading to sustained inflamma-
ion and oxidative/genotoxic stress. Subjects with the
ame pro-inflammatory polymorphisms may respond in
he same exaggerated manner to these non-H pylori bac-
eria, thus maintaining the pro-neoplastic drive. This
ay explain why H pylori is not required in the latter
tages of gastric carcinogenesis and why it is often absent
rom gastric tumor tissue.
It is essential to consider the possible mechanism by
hich the TLR4896AG polymorphism increases the
isk of gastric carcinoma and its precursors. The poly-
orphism was originally described by Arbour et al,13 and
as associated with hyporesponsiveness to inhaled LPS.
lveolar epithelial cells and macrophages derived from
hese subjects exhibited decreased response to LPS stim-
lation. However, this apparent hyporesponsiveness to
PS is actually translated clinically to increased risk of
erious outcomes to infections by Gram-negative bacteria
nd even some viruses. Examples include an increased
isk of septic shock,18,27 inflammatory bowel disease17
able 4. Genotype Frequencies and Adjusted Odds Ratios (O





(n  52) OR (95% CI)
A/A 194 51 1.0
A/G 16 1 0.2 (0.02–1.7
G/G 1 0
able 5. Combined Effect of IL-1 and TLR4 Polymorphisms









either 286 115 1 (Referent)
L-1a only 295 299 2.4 (1.8–3.2)
LR4896 A/G or
G/G only
23 29 3.0 (1.6–5.4)
L-1 and TLR4 26 53 5.0 (3.0–8.3)
I, confidence interval; OR, odds ratio.
cCarriage of IL-1B-511T and/or homozygous IL-1RN VNTR allele 2.nd severe respiratory syncytial virus bronchiolitis in in-
ants.28 The latter association is likely mediated through
he respiratory syncytial virus-F protein, which is thought
o act as a TLR4 ligand.29 It is therefore clear that although
he original functional significance of the mutation was
efined as hyporesponsiveness to LPS challenge, several
ines of evidence indicate that the host suffers serious
onsequences due to this apparent insensitivity. This is
ntirely born out in our study as carriers of the G allele
ad an increased risk of severe gastric damage, manifest
s the highest inflammatory and atrophy scores, lowest
astric acid outputs, and ultimately an increased risk of
oncardia gastric carcinoma.
How then does a polymorphism that is thought to
lunt the response to LPS lead to severe damage in
esponse to H pylori infection? The answer is not entirely
lear, but may lie in the nature of the host’s overall
esponse to this LPS and peptidoglycan attack. Failure to
andle the invasion by appropriately recognizing and
ctivating the necessary pathways may lead to an imbal-
nce of pro- and anti-inflammatory mediators. A very
legant demonstration of this phenomenon was recently
eported by Higgins et al.20 The authors infected TLR4
efective C3H/HeJ mice and their wild-type counterparts
C3H/HeN) with an aerosol of Bordetella pertussis (a Gram-
egative bacterium that causes whooping cough) and
onitored the course of the infection and its conse-
uences over several weeks. The course of the infection
as more severe in the TLR4-defective than the wild-type
ice, and this was associated with enhanced inflamma-
ory cytokine production, cellular infiltration, and severe
athologic changes in the lungs. Most interestingly, Hig-
ins et al20 showed that signaling through TLR4 in re-
ponse to bacterial infection activated IL-10 production,
hich promoted IL-10-producing T cells and controlled
nflammatory pathology during infection in normal, but
ot TLR4-defective mice. It is therefore likely that the
evere tissue damage observed in the TLR4-defective mice
as due to the deficiency of the anti-inflammatory IL-10,
hich in turn, accentuated the pro-inflammatory de-
tructive tissue response.
TLRs have the ability to recognize pathogens or patho-
en-derived products and initiate signaling events lead-
ng to activation of innate host defenses.11 Signaling by
LRs induces antimicrobial genes and pro-inflammatory
and Cornfield 95% Confidence Intervals [CIs]) for Carriers of
astric Cardia Cancer and Controls, U.S. Study
Esophageal
denocarcinoma
(n  107) OR (95% CI)
Gastric cardia
adenocarcinoma
(n  123) OR (95% CI)
97 1.0 110 1.0





























































































March 2007 TLR4 MUTATION AND GASTRIC CANCER 911ory responses.30 Signals that recruit neutrophils and
ctivated macrophages contribute to the killing of mi-
robes, but more importantly, they also lead to activation
f adaptive immune responses. In the case of H pylori
nfection, it is generally accepted that TLRs, in addition
o other receptors such as Nod1,31 are at least partly
nvolved in the initial recognition of the bacterium. How-
ver, there has been much debate about whether H pylori’s
PS is recognized by TLR4 or TLR2 (whose natural li-
ands include peptidoglycan, lipopeptides, and lipotei-
hoic acid from Gram-positive bacteria). In particular,
here is controversy about whether gastric epithelial cells
xpress TLR4 and whether the LPS of H pylori is involved
n the signaling pathways leading to production of proin-
ammatory cytokines.
Kawahara et al32 showed that guinea pig gastric pit
ells expressed TLR4 and other TLRs. Schmausser et al33
onfirmed that TLR4, TLR5, and TLR9 were expressed by
uman noninflamed gastric epithelium and in chronic
ctive H pylori-induced gastritis. More recently, the same
uthors demonstrated expression of TLR4 and TLR5 on
astric carcinoma cells and precursor lesions (intestinal
etaplasia and dysplasia).34 In contrast, Backhed et al35
ound no TLR4 expression in any primary antral cell
reparations, and also showed that gastric mucosal rec-
gnition of H pylori is independent of TLR4. Similarly,
mith et al36 investigated whether TLR2, TLR4, and
LR5 were required for NF-B activation and induction
f chemokine mRNA expression. They showed that gas-
ric epithelial cells recognize and respond to H pylori
nfection at least in part via TLR2 and TLR5, and that the
pylori LPS is a TLR2 and not a TLR4 agonist. Similarly,
epper et al37 demonstrated that H pylori LPS-induced
ell activation is mediated through TLR2, and that LPS
rom some H pylori strains were able to antagonize TLR4.
hey postulated that the antagonistic activity of H pylori
PS from certain strains, as well as the activation via
LR2, might give the bacterium an advantage over the
ost by allowing evasion of the innate immune system.
andell et al,38 using LPS derived from clinical isolates,
howed that the cytokine-inducing activity of H pylori
PS was mediated by macrophage TLR4.
In summary, it is likely that TLR2 is more relevant to
ecognition of H pylori LPS by gastric epithelial cells,
hile TLR4 is relevant in some capacity in the context of
acrophage/monocyte or other dendritic cell popula-
ions. TLR4 could also be activated by endogenous li-
ands produced during stress or cell damage.39 Such
igands include heat-shock protein 60, EDA domain of
bronectin and hyaluronan, and it is conceivable that
evere gastritis with inflammation and matrix turnover
ould also lead to activation of TLR4. As such, both
xogenous factors (eg, H pylori and other bacteria grow-
ng in an achlorhydric environment) and endogenous
actors (eg, byproducts of tissue damage) could be rele-
ant to TLR4. It appears that genetic polymorphisms inhe TLR4 gene have an important impact on this process,
nd our findings should act as a stimulus for further
esearch into the role that TLRs and other mediators of
he innate immune response play in H pylori-related dis-
ase and other Gram-negative bacterial infections.
In conclusion, our findings demonstrate a significant
ssociation between the TLR4 Asp299Gly polymorphism
nd increased risk of noncardia gastric carcinoma and its
recursors. Our results further emphasize the impor-
ance of genetic variability in the pathogenesis of micro-
ially induced chronic inflammatory diseases, including
eoplasia.
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